Login to Your Account


Avexxin AS is a testament to perseverance. Over several decades, Berit Johansen, the company's chief scientific officer, conducted basic research into the chronic inflammatory process, both as a visiting scientist at Cambridge, Mass.-based Biogen Inc. and as a researcher at multiple academic institutions. Johansen's understanding of the intracellular mechanisms of chronic inflammatory diseases, beginning with psoriasis, led to the 2005 incorporation of Avexxin, based on Trondheim, Norway. It took another decade for the company to achieve proof of concept for the topical formulation of its lead compound, AVX001.

LONDON – Going back to the roots of antibiotic discovery, a new Oxford University spinout has turned to natural product libraries to uncover recurring motifs that can be translated into novel synthetic chemistry.

SHANGHAI – Newly founded biopharma Harbour Biomed Therapeutics Ltd., of Shanghai, has acquired privately held Harbour Antibody BV, of Cambridge, Mass.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: